Takeda pays $60M upfront with $600M in milestones
roughly sixty million upfront with the remaining six hundred million tied to milestones and royalties
in a CNBC interview about the Takeda deal
Where it comes from
Takeda deal lets us scale our capabilities: Insilico Medicine CEOWhat the article says
Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery. He breaks down the ...
CNBC